Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other financing activities (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Other financing activities for 3 consecutive years, with $75000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other financing activities changed N/A to $75000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $200000.0, a N/A change, with the full-year FY2025 number at $200000.0, changed N/A from a year prior.
  • Other financing activities was $75000.0 for Q2 2025 at TScan Therapeutics, down from $125000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $748000.0 in Q2 2021 to a low of -$960000.0 in Q3 2021.
  • A 3-year average of $74857.1 and a median of $125000.0 in 2025 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 123.96% in 2022; the steepest drop was 123.96% in 2022.
  • TScan Therapeutics' Other financing activities stood at -$960000.0 in 2021, then soared by 109.79% to $94000.0 in 2022, then dropped by 20.21% to $75000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Other financing activities are $75000.0 (Q2 2025), $125000.0 (Q1 2025), and $94000.0 (Q4 2022).